Vivaspin 2 (10,000 MWCO Hydrosart) from Sartorius AG

Products	Vivaspin 2 (10,000 MWCO Hydrosart) from Sartorius AG
Company	Sartorius AG
Item	Vivaspin 2 (10,000 MWCO Hydrosart)
Price
Description	The new Vivaspin 2 bridges the gap between the 500 l and 4 ml centrifugal concentrators. This device combines the speed of the classic Vivaspin products with low internal surface and membrane area for superior recoveries from very dilute solutions. Available with a choice of PES, Cellulose Triacetate membranes, Vivaspin 2 offers the highest flexibility for process optimisation. Also unique to the Vivaspin 2, is the choice of directly pipetting the concentrate from the dead stop pocket built into the bottom of the concentrator, or alternatively reverse spinning into the concentrate recovery cap which can then be sealed for storage.
Info	Sartorius AG Weender Landstrasse 94-108 D-37075 Goettingen, Germany Phone: +49.551.308.0 Fax: +49.551.308.3289 Sartorius North America, Inc. Biolab - Biotechnology Division 131 Heartland Blvd. Edgewood, NY 11717 USA Toll-free: 877-452-2345 Fax: 631-253-5460 Customer Service: +49.551.308.0 Fax Number: +49.551.308.3289 Web Site: http://www.sartorius.com

NOTE: Price information is approximate list price and actual prices may vary.

TAG: Vivaspin MWCO Hydrosart from Sartorius

...RS are multi-functional mixing devices. Stepping m... solid, heavy-duty durable shaker to provide a uni...ature. Regulated action scale for all modes. Micro...trol time, continuous time, action scale and speed...

Finnigan LTQ FT from Thermo Scientific

PDQuest 10-User Network License from Bio-Rad

Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation

Biology Products:

Orbital Shaker from Major Science Finnigan LTQ FT from Thermo Scientific PDQuest 10-User Network License from Bio-Rad Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation

(Date:11/23/2009)...wine vaccine available for the H1N1 virus has been...virus. The vaccination marks the first time vaccin... pandemic flu., Iowa State University,s Hank Har...ccine this summer and has been shipping preventive...nois for several weeks., The latest vaccines wer...

(Date:11/23/2009)...studies reveal in unprecedented detail how the rib...ew proteins and guide them toward their destinatio...dynamics flexible fitting (MDFF) to examine the in...ular partners. , The first study, in Proceedin...the intimate signaling between the ribosome and an...

(Date:11/23/2009)... General Medical Sciences (NIGMS), part of the Nat....3 million for grants in scientific areas it ident... the GO grant program to stimulate biomedical rese...merican Recovery and Reinvestment Act (Recovery Ac...to have a significant impact on a field of biomedi...

Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2 Computational microscope peers into the working ribosome 2 Computational microscope peers into the working ribosome 3 NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2 NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3 HeartWare to Present at Upcoming Investment Conferences in November 60817 1 HeartWare to Present at Upcoming Investment Conferences in November 60817 2 Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 1 Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 2 Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 3 SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 1 SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 2 SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 3 SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 4 SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 5

[0] Iowa State researcher produces, ships only H1N1 vaccine available for swine [0] Computational microscope peers into the working ribosome [0] NIGMS invests in scientific Grand Opportunities with Recovery Act funds

..., MD. (September 6, 2007) - The American Society o...ecipients of its 2007 awards. These awards were pr...ld jointly with the Botanical Society of America a...an Society of Plant Taxonomists July 7-11, 2007 in... 2007 award winners in 10 different categories:, F...

...., Sept. 5 bioMETRX, Inc. (OTC,Bulletin Board: BM...,products, today announced that it has acquired a ...trics to secure portable locks. The company belie...ock,market. For many years, consumers have been us...on locks, to secure personal belongings in lockers...

...ST LAFAYETTE, Ind. - A biomedical engineer at Purd...m cardiopulmonary resuscitation that promises to b...eases nourishing blood flow through the heart by 2...que is desperately needed because conventional CPR...pending on how fast rescuers are able to respond a...

Other Biology News:The American Society of Plant Biologists announces 2007 awards 2 The American Society of Plant Biologists announces 2007 awards 3 The American Society of Plant Biologists announces 2007 awards 4 The American Society of Plant Biologists announces 2007 awards 5 bioMETRX, Inc. Acquires Patent for Biometric Padlock 2 New CPR promises better results by compressing abdomen, not Chest 2 New CPR promises better results by compressing abdomen, not Chest 3 New CPR promises better results by compressing abdomen, not Chest 4

The American Society of Plant Biologists announces 2007 awards bioMETRX, Inc. Acquires Patent for Biometric Padlock New CPR promises better results by compressing abdomen, not Chest

(Date:11/19/2009)..., BLAUVELT, N.Y., Nov. 19 Dr. Mate...extract, responds to a press release issued on Nov...rian company for making false and self-serving sta...nces. ,, Dr. Hidvegi stated from his office in...hat research on Avemar does not apply to AveULTRA,...

(Date:11/19/2009)..., NEW YORK, Nov. 19 NeoS... it has sent the following letter to its sharehold...ber 30, 2009, of China Biopharmaceuticals Holdings...mpany based in the People,s Republic of China. The...n Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prim...

(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PR... Decision Resources find that the leading driver o...Europe is broad-spectrum activity against gram-pos...ety of organisms that can cause nosocomial pneumon...look primarily for agents that provide appropriate...

(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeu...patient in a randomized Phase 2B study of AEG35156...velopment for multiple oncology indications. ,,...se 2 Study of the X-Linked Inhibitor of Apoptosis ...h High-dose Cytarabine and Idarubicin in AML Follo...

Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2 NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2 NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3 Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2 Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3 Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2

[0] American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor [0] NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company [0] Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe [0] Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)